1. Home
  2. Additional clinical information

FIGO staging for carcinoma of the endometrium

This document is a quick and concise evidence-based summary to provide additional information, instruction, or guidance to complement a treatment protocol or clinical resource document. 

International Federation of Gynaecology and Obstetrics (FIGO) staging for carcinoma of the endometrium r

Stage Description
Stage I* Tumour confined to the corpus uteri
IA* No or less than half myometrial invasion
IB* Invasion equal to or more than half of the myometrium
Stage II* Tumour invades cervical stroma but does not extend beyond the uterus**
Stage III* Local and/or regional spread of the tumour
IIIA* Tumour invades the serosa of the corpus uteri and/or adnexae#
IIIB* Vaginal and/or parametrial involvement#
IIIC* Metastases to pelvic and/or para-aortic lymph nodes#
IIIC1* Positive pelvic nodes
IIIC2* Positive para-aortic lymph nodes with or without positive pelvic lymph nodes
Stage IV* Tumour invades bladder and/or bowel mucosa, and/or distant metastases
IVA* Tumour invasion of bladder and/or bowel mucosa
IVB* Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes

*  Either G1, G2, or G3 (G=grade).
** Endocervical glandular involvement only should be considered as stage I and no longer as stage II.
#  Positive cytology has to be reported separately without changing the stage.

On this page
Expand all Collapse all Back to top
[%id%]
[%title%]
[%abstract%]

Version 2

Date Summary of changes
31/05/2017

Transferred to new eviQ website. Version number change to V.2.

Previous website ID: 298
22/05/2020 Document reviewed by medical oncology reference committee on 30/08/2019. No changes. Next review 31/12/2021.
20/08/2021 Document reviewed electronically by medical oncology reference committee. No changes. Next review in 2 years.

While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3060

20 Apr 2024